Skip to main content

Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma With Hans Lee, MD

Oncology Data Advisor® · Response Patterns of Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Hans Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Hans Lee, the Director of Multiple Myeloma Clinical Research at MD Anderson, presented his team's research from the LINKER-MM1 study, which sought to evaluate response patterns of linvoseltamab for relapsed/refractory multiple myeloma. Later, Dr. Lee sat down with Oncology Data Advisor to further discu...

Continue reading

Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD

Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 study which investigated odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).   Oncology...

Continue reading

Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD

Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hematologic malignancies stay local. In this podcast episode, Dr. Patel-Donnelly sits down with Oncology Data Advisor to discuss her session, share some o...

Continue reading

Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD

Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long-term follow up results from the ELEVATE-TN study, which investigated acalabrutinib plus or minus obinutuzumab for previously untreated patients with ...

Continue reading

Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD

Oncology Data Advisor® · Mitigating the Effects of Neighborhood Disadvantage in Acute Myeloid Leukemia: Brittany Ragon, MD   At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Brittany Ragon, Adult Leukemia and Transplant Specialist at Levine Cancer Institute, sat down with Oncology Data Advisor to discuss her presentation on neighborhood disadvantages associated with inferior overall survival outcomes for patients with acute myeloid leukemia (AML). In additio...

Continue reading

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting With David Andorsky, MD

Oncology Data Advisor® · Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of h...

Continue reading

Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes With Christopher Su, MD

Oncology Data Advisor® · Financial Hardship Experienced During Transplant in Myelodysplastic Syndromes: Christopher Su, MD At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Christopher Su, MD, a Hematologist at the Fred Hutchinson Cancer Center, presented his research regarding financial hardships experienced in the transplant setting for myelodysplastic syndromes (MDS). Dr. Su then set down with Oncology Data Advisor to further discuss his study, the res...

Continue reading

Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD

Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss the results from the ELM-2 study in which the efficacy of odronextamab was investigated for maintaining functionality and quality of life in patients ...

Continue reading

Advancing Inclusion for Blood Donation Systems for Marginalized Groups With Warren Fingrut, MD

Oncology Data Advisor® · Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD At the recent American Society of Hematology (ASH) Annual Meeting, Warren Fingrut, MD, a Transplant and Cell Therapy Physician at MD Anderson Cancer Center and Founder and Director of Stem Cell Club, a donor recruitment organization based in Canada, sat down with Oncology Data Advisor to discuss his team's research and presentation addressing disparities experienced by m...

Continue reading

Oncology Data Advisor at the American Society of Hematology (ASH) 2023 Annual Meeting

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more! Oncology Data Advisor® · Oncology D...

Continue reading

Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD

Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss his presentation on the results of research regarding momelotinib in treatment of myelofibrosis. This podcast episode was recorded live by Oncology Dat...

Continue reading

Pioneering the Field of Stem Cell Biology With Irving Weissman, MD

At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Irving Weissman, Director of the Institute of Stem Cell Biology and Regenerative Medicine at Stanford University, received the 2022 Wallace H. Coulter Award for Lifetime Achievement in Hematology. In this interview, Dr. Weissman tells the story of how he entered the field, describes the monumental contributions he has made in hematology and oncology, and shares advice for medical students who are interested in becoming involved in basic science research.  

Continue reading

Additional Advances in Multiple Myeloma Research and Clinical Trials: With Sarah Holstein, MD, PhD

Oncology Data Advisor™ · Additional Advancements in Research: Multiple Myeloma Earlier this year, Dr. Sarah Holstein of the University of Nebraska Medical Center participated in a two-part continuing medical education (CME) activity regarding practice-changing strategies and improved patient outcomes in the treatment of multiple myeloma (MM). With many updates and improvements in the treatment of MM since recording, Dr. Holstein joins OncData to share her knowledge and talk about wh...

Continue reading

i3 Health Publishes T-Cell Lymphoma Education Study in American Society of Hematology Online Program

i3 Health's study focusing on the effectiveness of an online continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of therapeutic advances in T-cell lymphoma (TCL) has been published as a 63rd American Society of Hematology (ASH) Annual Meeting & Exposition online abstract

Continue reading

Safely Reducing Patient Hospital Stay After CAR T-Cell Therapy: Remote Patient Monitoring With Morie Gertz, MD

While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through inpatient admission for frequent monitoring; however, an onsite hospital stay can create a significant burden for the patient. As part of a study recent...

Continue reading

Addressing Racial Disparities in Clinical Trial Recruitment: Alexis A. Thompson, MD, MPH

One of the issues surrounding hematology care is the underrepresentation of racial and ethnic minorities in clinical trials. At the recent 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, Alexis A. Thompson, MD, MPH, past President of ASH and Professor of Pediatrics at Northwestern University's Feinberg School of Medicine, shared her thoughts on strategies for remedying these disparities so that more inclusive care can be provided for patients with h...

Continue reading

CC-486 Effective for Acute Myeloid Leukemia

The oral hypomethylating agent CC-486, when administered in an escalated dosing schedule (>7 days per 28-day treatment cycle), has been shown to be effective and well tolerated for patients with acute myeloid leukemia (AML) experiencing their first relapse, according to results of a study presented at American Society of Hematology (ASH) Annual Meeting. For the phase 3 international, randomized, double-blind QUAZAR AML-001 trial (NCT01757535), 472 patients with AML were enrolled. To be eligib...

Continue reading

Myeloma: Bortezomib Overcomes Renal Impairment or del17p

​Twelve-year follow-up results of the HOVON-65/GMMG-HD4 study reveal that among transplant-eligible patients with newly diagnosed multiple myeloma, those with renal impairment or chromosome deletion (del) 17p experience the most survival benefit from bortezomib-based induction and maintenance therapy. This prospective, open-label phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the German Multicenter Myeloma Group (GMMG) enrolled 827 eligible patients aged 18 to 6...

Continue reading